Medical and nonpharmacologic treatment options for VMS range in efficacy and risk/benefit profile; a short slide show offers a topline look at how many compare.
For many women navigating the menopausal transition, vasomotor symptoms (VMS) such as hot flashes and night sweats are more than just inconvenient—they’re disruptive, persistent, and often undertreated. Progressively deeper understanding of the neuroendocrine mechanisms behind these symptoms is driving changes in the therapeutic landscape.
From established hormone therapies to novel nonhormonal agents and integrative approaches, women have an increasing number of options to help them tailor treatment of VMS that aligns with their specific needs and preferences.
The short slide show above provides a quick refresher on the choices for both medical and alternative and complementary treatment, comparing their efficacy key benefits and risks, and suggesting who the best candidate for each type of therapy might be.
Check out all the Patient Care ACOG 2025 coverage.
Lebrikizumab Demonstrates Efficacy, Safety in Patients With Skin of Color With AD
June 11th 2025RAD 2025. Lebrikizumab improved skin clearance, itch, and pigmentation in patients with skin of color and atopic dermatitis, with strong safety data through 24 weeks, according to late-breaking data.